Harrington Investments INC Sells 1,575 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Harrington Investments INC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,802 shares of the biopharmaceutical company’s stock after selling 1,575 shares during the period. Harrington Investments INC’s holdings in Gilead Sciences were worth $1,829,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC grew its holdings in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 311,285 shares of company stock worth $31,284,910 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Royal Bank of Canada boosted their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Wolfe Research started coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $111.44 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market cap of $138.78 billion, a P/E ratio of 301.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The firm’s 50-day simple moving average is $101.82 and its 200-day simple moving average is $92.71. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.